is sitagliptin a glp 1 First Time: Orally Available GLP-1 Agonist More Effective than DPP-IV Inhibitor | DZD DPP-4 inhibitors and GLP-1RAs: cardiovascular

While the nephroprotective effects of SGLT2i were initially derived from secondary endpoints of CV outcome trials (CVOTs), direct confirmation came from dedicated kidney focused trials: CREDENCE (Perkovic et al NEJM 2019| NephJC Summary), DAPA-CKD (Heerspink et al NEJM 2020| NephJC Summary) and finally EMPAKIDNEY (Herrington et al NEJM 2023| NephJC Summary)

Find Your Perfect Treatment Use our treatment planning tool to find the best solutions for your aesthetic and wellness concerns

Med Gas Res 5(1):1

Realistic expectations essential, maintaining remaining vision versus expecting major improvements

You do not start at the maximum dose